Vertex Pharmaceuticals (NASDAQ:VRTX) is one of the best QQQ Stocks to invest in. On July 1, Vertex Pharmaceuticals announced that the US FDA approved the expanded use of its genetic therapy, CASGEVY, to treat children as young as 2 years old. This makes it the first and only approved gene therapy for patients of this age range suffering from sickle cell disease or transfusion-dependent beta thalassemia.
This regulatory milestone makes approximately 5,500 additional children in the US eligible for the one-time treatment. By providing earlier access to the therapy, clinicians hope to address the progression of these life-shortening diseases before significant, irreversible organ damage occurs.
Vertex Pharmaceuticals (NASDAQ:VRTX) established a network of over 75 authorized treatment centers across the U.S. to manage patient access and care. While this approval is specific to the US market, the company noted that regulatory reviews for similar label expansions are currently underway in the UK and the Kingdom of Saudi Arabia.
Vertex Pharmaceuticals (NASDAQ:VRTX) operates as a biotechnology company in the US, Europe, and internationally.
While we acknowledge the potential of VRTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
This regulatory milestone makes approximately 5,500 additional children in the US eligible for the one-time treatment. By providing earlier access to the therapy, clinicians hope to address the progression of these life-shortening diseases before significant, irreversible organ damage occurs.
Vertex Pharmaceuticals (NASDAQ:VRTX) established a network of over 75 authorized treatment centers across the U.S. to manage patient access and care. While this approval is specific to the US market, the company noted that regulatory reviews for similar label expansions are currently underway in the UK and the Kingdom of Saudi Arabia.
Vertex Pharmaceuticals (NASDAQ:VRTX) operates as a biotechnology company in the US, Europe, and internationally.
While we acknowledge the potential of VRTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
24 days ago
